Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH331624FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for patients with long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX701 for wilson disease; UX053 for glycogen storage disease type III; GTX-102 for the treatment of angelman syndrome in partnership with GeneTx; and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04,2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11,2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08,2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09,2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ultragenyx Pharmaceutical Inc – Key Facts
Ultragenyx Pharmaceutical Inc – Key Employees
Ultragenyx Pharmaceutical Inc – Key Employee Biographies
Ultragenyx Pharmaceutical Inc – Major Products and Services
Ultragenyx Pharmaceutical Inc – History
Ultragenyx Pharmaceutical Inc – Company Statement
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ultragenyx Pharmaceutical Inc – Business Description
Product Category: Collaboration and License Revenue
Performance
Product Category: Crysvita
Overview
Performance
Product Category: Dojolvi
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: Royalty Revenue
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: North America
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc – Corporate Strategy
Ultragenyx Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Ultragenyx Pharmaceutical Inc – Strengths
Ultragenyx Pharmaceutical Inc – Weaknesses
Ultragenyx Pharmaceutical Inc – Opportunities
Ultragenyx Pharmaceutical Inc – Threats
Ultragenyx Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04, 2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11, 2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08, 2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09, 2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases
Oct 28, 2020: Ultragenyx announces proposed public offering of common stock
Oct 27, 2020: Ultragenyx reports third quarter 2020 financial results and corporate update
Oct 23, 2020: Ultragenyx and Solid Biosciences announce strategic collaboration to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy
Sep 02, 2020: Ultragenyx appoints Mardi C. Dier as Chief Financial Officer
Sep 01, 2020: Ultragenyx expands leadership team and appoints Ernie Meyer as Chief Human Resources Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ConforMIS Inc (CFMS):医療機器:M&Aディール及び事業提携情報
    Summary ConforMIS Inc (ConforMIS) is a medical technology company that manufactures, develops, and markets joint replacement implants. The company’s knee replacement implant products include iTotal CR a cruciate-retaining product, iTotal PS a posterior cruciate ligament substituting product, and iDu …
  • CaixaBank SA:企業の戦略・SWOT・財務情報
    CaixaBank SA - Strategy, SWOT and Corporate Finance Report Summary CaixaBank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • MVV Energie AG (MVV1):企業の財務・戦略的SWOT分析
    MVV Energie AG (MVV1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Centene Corp (CNC):企業の財務・戦略的SWOT分析
    Centene Corp (CNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • General Electric Co (GE):企業の財務・戦略的SWOT分析
    General Electric Co (GE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sygnity SA (SGN):企業の財務・戦略的SWOT分析
    Sygnity SA (SGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bonvests Holdings Limited:戦略・SWOT・企業財務分析
    Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Winbond Electronics Corporation (2344):企業の財務・戦略的SWOT分析
    Winbond Electronics Corporation (2344) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Guangxi Investment Group Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Guangxi Investment Group Co Ltd (Guangxi Investment) is a diversified company. The company’s business segments include energy, aluminium, financial, cultural tourism, international business and medical and medical health business. Its energy business provides investments in the construction …
  • Mitsubishi Tanabe Pharma Corp (4508):製薬・医療:M&Aディール及び事業提携情報
    Summary Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, d …
  • Madrigal Pharmaceuticals Inc (MDGL):企業の財務・戦略的SWOT分析
    Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Proactis Holdings Plc (PHD):企業の財務・戦略的SWOT分析
    Summary Proactis Holdings PLC (Proactis) is a technology company that develops and provides spend control and eprocurement solutions. The company offers solutions such as source-to-contract, purchase-to-pay, eCommerce and global framework. It provides source-to-contract solutions for supplier manage …
  • Vectra Bank Colorado:企業の戦略・SWOT・財務情報
    Vectra Bank Colorado - Strategy, SWOT and Corporate Finance Report Summary Vectra Bank Colorado - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mylan N.V.:企業のM&A・事業提携・投資動向
    Mylan N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mylan N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Andhra Petrochemicals Ltd (500012):企業の財務・戦略的SWOT分析
    Andhra Petrochemicals Ltd (500012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Dan Hotels Corporation Ltd:戦略・SWOT・企業財務分析
    Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Chesapeake Lodging Trust:企業のM&A・事業提携・投資動向
    Chesapeake Lodging Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chesapeake Lodging Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • HealthCare Global Enterprises Ltd (HCG)-製薬・医療分野:企業M&A・提携分析
    Summary HealthCare Global Enterprises Ltd (HCG), formerly Curie Centre of Oncology Private Ltd is a healthcare service provider that offers medical care and treatment services. The company offers services such as clinical laboratory services, diagnosis services, medical oncology services, radiation …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Clinical Innovations LLC-医療機器分野:企業M&A・提携分析
    Summary Clinical Innovations LLC (Clinical Innovations), a subsidiary of Pritzker Group Company is a medical device company that offers healthcare products for women and infants. The company offers products such as safety heelsticks, traxi panniculus retractor, ROM plus membrane testing, tamponade s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆